The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

The FDA has cleared the Dexcom G7 15 Day continuous glucose monitoring system for individuals 18 years and older with diabetes.

DexCom, Inc. DXCM recently announced the FDA clearance for its 15-day wear G7 Continuous Glucose Monitoring (CGM) system, the ...

DexCom (NasdaqGS:DXCM) recently experienced a 14% price increase over the past week. This uptick coincides with the company's announcement of FDA clearance for the Dexcom G7 Continuous Glucose ...

Dexcom has announced that the U.S. Food and Drug Administration has cleared its G7 15 Day Continuous Glucose Monitoring ...

San Diego-based Dexcom submitted its 15-day G7 CGM to the FDA in October 2024. The company says its 15-day G7 also meets ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day ...

The US Food and Drug Administration has cleared the latest version to last 5 days longer than previously for adult users.

Credit: Dexcom. The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required.

The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting wearable on the market.